Correlation Between Merck and Mineralys Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Merck and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merck and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Merck Company and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Merck and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merck with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merck and Mineralys Therapeutics,.

Diversification Opportunities for Merck and Mineralys Therapeutics,

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between Merck and Mineralys is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Merck Company and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Merck is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merck Company are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Merck i.e., Merck and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Merck and Mineralys Therapeutics,

Considering the 90-day investment horizon Merck Company is expected to under-perform the Mineralys Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Merck Company is 3.2 times less risky than Mineralys Therapeutics,. The stock trades about -0.17 of its potential returns per unit of risk. The Mineralys Therapeutics, Common is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  1,241  in Mineralys Therapeutics, Common on August 30, 2024 and sell it today you would earn a total of  70.00  from holding Mineralys Therapeutics, Common or generate 5.64% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Merck Company  vs.  Mineralys Therapeutics, Common

 Performance 
       Timeline  
Merck Company 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Merck Company has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.
Mineralys Therapeutics, 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Merck and Mineralys Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Merck and Mineralys Therapeutics,

The main advantage of trading using opposite Merck and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merck position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.
The idea behind Merck Company and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world